Recce Pharmaceuticals up 6% on new antibiotic production milestone
Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
ECL | Ann:Removal from Official List COB 27 Nov 2017 (Price Sensitive) | 24/11/17 | 0 | 835 | |||
|
|||||||
ECL | Ann:Disclosure query (Price Sensitive) | 09/11/17 | 0 | 905 | |||
|
|||||||
ECL | Ann:Response to disclosure query (Price Sensitive) | 09/11/17 | 0 | 840 | |||
|
|||||||
ECL | Ann:Continuation of Suspension (Price Sensitive) | 09/11/17 | 0 | 874 | |||
|
|||||||
ECL | Ann:Director declaration | 19/09/17 | 0 | 741 | |||
|
|||||||
ECL | Ann:Director declaration | 19/09/17 | 0 | 870 | |||
|
|||||||
ECL | Ann:Half Yearly Annexure - 30 June 2017 (Price Sensitive) | 14/09/17 | 0 | 1.4K | |||
|
|||||||
ECL | Ann:Half Year Audit Review (Price Sensitive) | 13/09/17 | 0 | 676 | |||
|
See All Discussions